ATE455103T1 - Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate - Google Patents

Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate

Info

Publication number
ATE455103T1
ATE455103T1 AT06785361T AT06785361T ATE455103T1 AT E455103 T1 ATE455103 T1 AT E455103T1 AT 06785361 T AT06785361 T AT 06785361T AT 06785361 T AT06785361 T AT 06785361T AT E455103 T1 ATE455103 T1 AT E455103T1
Authority
AT
Austria
Prior art keywords
sup
phenylglycinamide
pyridylglycinamide
derivatives used
anticoagulation agents
Prior art date
Application number
AT06785361T
Other languages
English (en)
Inventor
Xiaojun Zhang
Alexandra A Nirschl
Yan Zou
Eldon Scott Priestley
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE455103T1 publication Critical patent/ATE455103T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06785361T 2005-06-24 2006-06-22 Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate ATE455103T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69407605P 2005-06-24 2005-06-24
US69407405P 2005-06-24 2005-06-24
PCT/US2006/024345 WO2007002313A2 (en) 2005-06-24 2006-06-22 Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants

Publications (1)

Publication Number Publication Date
ATE455103T1 true ATE455103T1 (de) 2010-01-15

Family

ID=37467511

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06785361T ATE455103T1 (de) 2005-06-24 2006-06-22 Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate

Country Status (6)

Country Link
US (1) US7456195B2 (de)
EP (1) EP1910298B1 (de)
AT (1) ATE455103T1 (de)
DE (1) DE602006011752D1 (de)
ES (1) ES2337831T3 (de)
WO (1) WO2007002313A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1828152B1 (de) * 2004-12-08 2008-08-20 Bristol-Myers Squibb Company Heterocyclische verbindungen als inhibitoren von faktor viia
TW200637843A (en) 2005-01-10 2006-11-01 Bristol Myers Squibb Co Phenylglycinamide derivatives useful as anticoagulants
TW200745062A (en) * 2005-12-23 2007-12-16 Bristol Myers Squibb Co Macrocyclic factor VIIA inhibitors useful as anticoagulants
JP2009539873A (ja) 2006-06-08 2009-11-19 ブリストル−マイヤーズ スクイブ カンパニー 抗凝固剤として有用な第ＶＩＩａ因子インヒビターとしての２−アミノカルボニルフェニルアミノ−２−フェニルアセトアミド類
PE20081775A1 (es) * 2006-12-20 2008-12-18 Bristol Myers Squibb Co Compuestos macrociclicos como inhibidores del factor viia
CN101631784A (zh) * 2006-12-20 2010-01-20 百时美施贵宝公司 用作抗凝血药的二环内酰胺凝血因子viia抑制剂
EP2191887A1 (de) 2008-11-26 2010-06-02 Polymers CRC Limited Anklickbare Dünnschichtverbundpolyamidmembrane
AR077695A1 (es) 2009-08-04 2011-09-14 Schering Corp Derivados de pirimidina como inhibidores del factor ixa
US20120196854A1 (en) 2009-10-06 2012-08-02 Kyowa Hakko Kirin Co., Ltd. Pharmaceutical composition comprising aromatic heterocyclic compound
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
AU2013250726B2 (en) 2012-04-20 2017-01-05 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
EP2858977A1 (de) 2012-06-08 2015-04-15 Bristol-Myers Squibb Company Makrocyclische faktor-viia-hemmer
US8987461B2 (en) 2012-12-06 2015-03-24 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
CN107873023B (zh) 2015-02-02 2021-07-23 福马治疗股份有限公司 作为hdac抑制剂的3-烷基-4-酰氨基-双环[4，5，0]异羟肟酸
UY36548A (es) 2015-02-05 2016-06-01 Bayer Cropscience Ag Derivados heterocíclicos condensados bicíclicos sustituidos por 2-(het)arilo como pesticidas
TW202400564A (zh) 2015-06-05 2024-01-01 美商艾佛艾姆希公司 作為除草劑之嘧啶氧基苯衍生物
AU2016288204B2 (en) * 2015-06-30 2020-11-05 Dana-Farber Cancer Institute, Inc. Inhibitors of EGFR and methods of use thereof
EP3319968A1 (de) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclische n-aminophenyl-amide als inhibitoren der histondeacetylase
RS62639B1 (sr) 2015-07-06 2021-12-31 Alkermes Inc Hetero-halo inhibitori histonskih deacetilaza
CN105481733A (zh) * 2015-12-30 2016-04-13 苏州诚和医药化学有限公司 一种一步法合成2-甲氧基-5-氨磺酰基苯甲酸甲酯的方法
CA3049443A1 (en) 2017-01-11 2018-07-19 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
CN111606827B (zh) * 2020-06-23 2022-10-25 内蒙古京东药业有限公司 一种制备依度沙班手性胺中间体的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2667864B2 (fr) * 1990-03-07 1994-08-05 Rhone Poulenc Sante Derives de n-phenyl glycinamides, leur preparation et les medicaments les contenant.
IL123986A (en) * 1997-04-24 2011-10-31 Organon Nv Medicinal compounds
ES2201396T3 (es) * 1997-12-04 2004-03-16 F. Hoffmann-La Roche Ag Derivados de la n - (4-carbamimido-fenil) -glicinamida.
EP1078917A4 (de) * 1998-02-17 2002-11-06 Ono Pharmaceutical Co Amidinoderivate und medikamente die diese als aktiven bestandteil enthalten
ATE274491T1 (de) * 1998-12-14 2004-09-15 Hoffmann La Roche Phenylglycin-derivate
EP1144373B1 (de) * 1999-01-13 2005-10-19 Genentech, Inc. Serinprotease-inhibitoren
EP1059302A1 (de) * 1999-06-08 2000-12-13 Aventis Pharma Deutschland GmbH Faktor VIIa Inhibitore
US6548694B2 (en) * 2000-05-23 2003-04-15 Hoffman-La Roche Inc. N-(4-carbamimidoyl-phenyl)-glycine derivatives
CA2428191A1 (en) * 2000-11-07 2002-05-30 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
DE10102322A1 (de) * 2001-01-19 2002-07-25 Merck Patent Gmbh Phenylderivate
RU2003132706A (ru) * 2001-04-06 2005-04-20 Байокрист Фармасьютикалз, Инк. (Us) Диариловые соединения в качестве ингибиторов сериновых протеаз
DE10139060A1 (de) * 2001-08-08 2003-02-20 Merck Patent Gmbh Phenylderivate
US6642386B2 (en) * 2002-02-06 2003-11-04 Hoffmann-La Roche Inc. N-(4-carbamimidoyl-phenyl)-glycine derivatives
US6821974B2 (en) * 2002-03-05 2004-11-23 Barbeau Pharma, Inc Stable pharmaceutical compositions
DE10214832A1 (de) 2002-04-04 2003-10-16 Merck Patent Gmbh Phenylderivate 4
JP2006517589A (ja) * 2003-02-11 2006-07-27 ブリストル−マイヤーズ　スクイブ　カンパニー セリンプロテアーゼ・インヒビターとして有用なベンゼンアセトアミド化合物
WO2004072101A2 (en) 2003-02-11 2004-08-26 Bristol-Myers Squibb Company Phenylglycine derivatives useful as serine protease inhibitors
EP1828152B1 (de) * 2004-12-08 2008-08-20 Bristol-Myers Squibb Company Heterocyclische verbindungen als inhibitoren von faktor viia
TW200637843A (en) * 2005-01-10 2006-11-01 Bristol Myers Squibb Co Phenylglycinamide derivatives useful as anticoagulants
AU2006298727B2 (en) * 2005-10-05 2011-11-17 F. Hoffmann-La Roche Ag Naphthyridin derivatives
US7618985B2 (en) * 2005-12-08 2009-11-17 N.V. Organon Isoquinoline derivatives

Also Published As

Publication number Publication date
EP1910298B1 (de) 2010-01-13
EP1910298A2 (de) 2008-04-16
US7456195B2 (en) 2008-11-25
US20070003539A1 (en) 2007-01-04
WO2007002313A3 (en) 2007-05-18
ES2337831T3 (es) 2010-04-29
WO2007002313A2 (en) 2007-01-04
DE602006011752D1 (de) 2010-03-04

Similar Documents

Publication Publication Date Title
ATE455103T1 (de) Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
WO2008005368A3 (en) Piperazines as p2x7 antagonists
ATE389635T1 (de) Pharmazeutisch wirksame piperidinderivate
NO20070532L (no) Substituerte 2-alkyl-kinazolinonderivater som PARP-inhibitorer
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
WO2007014054A3 (en) Benzenesulfonamide inhibitor of ccr2 chemokine receptor
SE0400284D0 (sv) Novel compounds
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
NO20080865L (no) Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer
ATE283253T1 (de) Substituierte aminopropoxyarylderivate als lxr agonisten
NO20082389L (no) 2,3,4-trifenylimidazolinderivater som inhibitor av interaksjonen mellom P53- og MDM2-proteiner for anvendelse som antikreftmidler
MX2009006689A (es) Inhibidores viia de los factores macrociclicos utiles como anticoagulantes.
ECSP055867A (es) Derivados de pirrolopirimidina
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
ME01992B (me) Jedinjenje diarilhidantoina
EA200970585A1 (ru) Бензамидные производные как агонисты ер-рецепторов
ES2571779T3 (es) Inhibidores de cinasa a base de nicotinamida
TW200745062A (en) Macrocyclic factor VIIA inhibitors useful as anticoagulants
NO20075734L (no) Tiofenforbindelser og trombopoietin reseptoractivatorer
NO20072753L (no) 3-Etylidenhydrazinosubstituerte heterocykliske forbindelser som trombopoietinreseptoraktivatorer
ATE476431T1 (de) Piperidin- und azetidinderivate als glyt1- inhibitoren
DE602004009200D1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
EA200900631A1 (ru) Замещённые пиразолы и триазолы, как ингибиторы кбв (кинезин-белок веретена)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties